Logo

Abstract

Background: Follistatin (FST) is glycoprotein, otherwise called activin restricting protein, is an endogenously created protein that ties activin a with high fondness and restrains its bioactivity. The essential capacity of FST is the authoritative and bioneutralization of individuals from the transforming growth factor-beta superfamily and activin a specifically. FST advances adipogenic separation of begetter cells. FST has been embroiled in aggravation and renovating, any adjustment in the level of FST, which might be a determinant of the seriousness of irritation, or tissue phenotypic change. Atherosclerosis is a dynamical procedure that rises up out of the interchange between lipid digestion, irritation, and inborn insusceptibility. Materials and Methods: The study was applied on 88 people aged 30–69 years, included 65 patients suffering from atherosclerosis disease. The FST level was assessed by enzyme-linked immunosorbent assay kit. Results: The results exhibited significant increase (P < 0.05) in FST serum level of atherosclerosis patients (11.92 ± 2.522 ng/ml) compared with healthy group (0.6703 ± 0.1012 ng/ml). Significant increase (P < 0.05) in FST serum level of female atherosclerosis patients group (10.912 ± 0.5823 ng/ml) compared with male atherosclerosis patients group (2.892 ± 0.3849 ng/ml) and also compared with male and female healthy group (0.136 ± 0.0721 ng/ml, and 0.799 ± 0.2023 ng/ml), respectively. In addition, there was significant increase (P < 0.05) in FST serum level of the healthy female group compared with the healthy male group. The results indicated that there was significant increase (P < 0.05) in FST serum level of age group of 60–69 years of atherosclerosis patients and has compared with other ages. The results showed significant increase (P > 0.05) in FST serum level in the obese weight of the atherosclerosis patients group have (8.286 ± 2.112 ng/ml) compared with (over weight and normal weight) have (4.266 ± 1.012 ng/ml and 2.221 ± 0.568 ng/ml ) respectively, and results showed significant increase (P > 0.05) in FST serum level in overweight (4.266 ± 1.012 ng/ml) compared to normal weight (2.221 ± 0.568 ng/ml). There was non-significant difference in FST serum level among healthy groups (obese weight, overweight, and normal weight) have 0.7685 ± 0.0121 ng/ml, 0.6615 ± 0.1311 ng/ml, and 0.5251 ± 0.2324 ng/ml, respectively. The results showed significant increase (P < 0.05) in FST serum level of patients group according to waist circumference (111–120 cm) compared with other waist. The results showed that significant increase (P < 0.05) in FST serum level in smokers atherosclerosis patients’ group has (13.974 ± 1.433 ng/ml) compared to nonsmokers of the atherosclerosis patients’ group, and healthy group nonsmokers have 5.949 ± 2.101 ng/ml and 0.6703 ± 0.1012 ng/ml, respectively, and nonsmokers of the atherosclerosis patients’ group compared with the healthy group nonsmokers. Conclusion: FST is the new biomarker for prognostic, staging, and detection of atherosclerosis disease.

Abstract Audio

No Audio file found

About the authors and Affiliations

	Name
	JPR Solutions

View Article File in pdf format.

Article File

View Article Citation Here.

How to Cite my Article.

Experimental Methods Keywords